Loading…
Neurological disorder characterised by recurrent seizures. Some cannabinoids have established anti-seizure efficacy for specific syndromes.
These compounds appear in related research or traditional use. Their position is not a recommendation or ranking.
Be the first to share what has helped with epilepsy.
Open the original papers, check their methods, and discuss what is relevant with a qualified professional.
Systematic Review · matched via Epilepsy · PubMed record (CORPUS-A)
PMID 42185726 ↗02Comparative Pharmacokinetics and Safety of Cannabidiol in a Powder Formulation, CBtru(®), vs an Oil-Based Formulation, Epidyolex(®), Under Fasted and Fed Conditions in Healthy Participants: A Randomized Open-Label Cross-Over Phase I StudyBendik I, et al. · CNS drugs · 2026Randomized Controlled Trial · matched via Epilepsy · open-access full text · PubMed record (CORPUS-A)
PMID 41888503 ↗03Aplicaciones terapéuticas por acción de los cannabinoidesPlancarte-Sánchez R, et al. · Gaceta medica de Mexico · 2019Systematic Review · matched via Epilepsy · PubMed record (CORPUS-A)
PMID 31219471 ↗04Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsyBirnbaum AK, et al. · Epilepsia · 2019Randomized Controlled Trial · matched via Epilepsy · PubMed record (CORPUS-A)
PMID 31247132 ↗05Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndromeThiele EA et al. · N Engl J Med · 2017CBD at 20 mg/kg/day significantly reduced drop seizure frequency in Lennox-Gastaut syndrome versus placebo.
PMID 28578495 ↗06Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokersRandomized Controlled Trial · matched via Epilepsy · PubMed record (CORPUS-A)
Outcome summaries extracted from the linked papers' curated records. Educational, not medical advice.
Figures are reported as published; study designs and populations vary. Works for Us does not interpret results or provide medical advice.